Personalizing medicine with clinical pharmacogenetics

Successful Translation of Pharmacogenetics into the Clinic

(2012) Elizabeth Phillips et al.   Molecular Diagnosis & Therapy

Pharmacogenetic Testing: Time for Clinical Practice Guidelines

(2011) U Amstutz et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacogenomics: “Noninferiority” Is Sufficient for Initial Implementation

(2011) R B Altman   CLINICAL PHARMACOLOGY & THERAPEUTICS

Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing

(2011) M V Relling et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacogenetics: From Bench to Byte— An Update of Guidelines

(2011) J J Swen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network

(2011) M V Relling et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy

(2011) S A Scott et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacoeconomic evaluation of warfarin pharmacogenomics

(2011) Joyce HS You   EXPERT OPINION ON PHARMACOTHERAPY

Is there a need for PGxceptionalism?

(2011) Muin J. Khoury et al.   GENETICS IN MEDICINE

Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in Taiwan

(2011) Pei Chen et al.   NEW ENGLAND JOURNAL OF MEDICINE

HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans

(2011) Mark McCormack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacogenomics and personalized medicine in clinical practice

(2011) Vangelis G Manolopoulos et al.   PHARMACOGENOMICS

Pharmacogenomics in the Assessment of Therapeutic Risks versus Benefits: Inside the United States Food and Drug Administration

(2011) Issam Zineh et al.   PHARMACOTHERAPY

Genetic Background of Patients from a University Medical Center in Manhattan: Implications for Personalized Medicine

(2011) Bamidele O. Tayo et al.   PLoS One

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups

(2010) N. A. Limdi et al.   BLOOD

Developing Pharmacogenetic Evidence Throughout Clinical Development

(2010) D K Burns   CLINICAL PHARMACOLOGY & THERAPEUTICS

Establishing Clinical Utility of Pharmacogenetic Tests in the Post-FDAAA Era

(2010) B J Evans   CLINICAL PHARMACOLOGY & THERAPEUTICS

Dealing With the Evidence Dilemma in Genomics and Personalized Medicine

(2010) M J Khoury   CLINICAL PHARMACOLOGY & THERAPEUTICS

What Is Clinical Utility and Why Should We Care?

(2010) L J Lesko et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases

(2010) Stuart A. Scott et al.   HUMAN MUTATION

Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI

(2010) Jessica L. Mega et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Characterization of 107 Genomic DNA Reference Materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1

(2010) Victoria M. Pratt et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”

(2010) David R. Holmes et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism

(2010) Mary V Relling et al.   LANCET ONCOLOGY

Personalized Medicine and Genomics: Challenges and Opportunities in Assessing Effectiveness, Cost-Effectiveness, and Future Research Priorities

(2010) Rena Conti et al.   MEDICAL DECISION MAKING

Genome-wide association studies in pharmacogenomics

(2010) Ann K. Daly   NATURE REVIEWS GENETICS

DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA

(2010) Lawrence J Lesko et al.   PHARMACOGENOMICS

A systematic review of cost–effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives

(2010) Talitha I Verhoef et al.   PHARMACOGENOMICS

Pharmacogenomics instruction in US and Canadian medical schools: implications for personalized medicine

(2010) James S Green et al.   PHARMACOGENOMICS

CombinedCYP2C9,VKORC1andCYP4F2frequencies among racial and ethnic groups

(2010) Stuart A Scott et al.   PHARMACOGENOMICS

Population-specific documentation of pharmacogenomic markers and their allelic frequencies in FINDbase

(2010) Marianthi Georgitsi et al.   PHARMACOGENOMICS

Practical recommendations for pharmacogenomics-based prescription: 2010 ESF–UB Conference on Pharmacogenetics and Pharmacogenomics

(2010) Laurent Becquemont et al.   PHARMACOGENOMICS

Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17

(2009) Alain Li-Wan-Po et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The Pharmacogenomics of Membrane Transporters Project: Research at the Interface of Genomics and Transporter Pharmacology

(2009) D L Kroetz et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin

(2009) David A Flockhart et al.   GENETICS IN MEDICINE

Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?

(2009)   GENETICS IN MEDICINE

Personal utility and genomic information: Look before you leap

(2009) Scott D Grosse et al.   GENETICS IN MEDICINE

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group

(2009) Steven M Teutsch et al.   GENETICS IN MEDICINE

Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy

(2009) Alan R. Shuldiner   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Germline Genetic Variation in an Organic Anion Transporter Polypeptide Associated With Methotrexate Pharmacokinetics and Clinical Effects

(2009) Lisa R. Treviño et al.   JOURNAL OF CLINICAL ONCOLOGY

An agenda for personalized medicine

(2009) Pauline C. Ng et al.   NATURE

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

(2009) Dongliang Ge et al.   NATURE

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

(2009) Ann K Daly et al.   NATURE GENETICS

Personalized medicine for clopidogrel resistance?

(2009) Jean-Sébastien Hulot et al.   Nature Reviews Cardiology

Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

Cytochrome P450 2D6

(2009) Ryan P. Owen et al.   Pharmacogenetics and Genomics

Pharmacogenomic genome-wide association studies: lessons learned thus far

(2009) James J Crowley et al.   PHARMACOGENOMICS

A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose

(2009) Fumihiko Takeuchi et al.   PLoS Genetics

Warfarin Pharmacogenetics: CYP2C9 and VKORC1 Genotypes Predict Different Sensitivity and Resistance Frequencies in the Ashkenazi and Sephardi Jewish Populations

(2008) Stuart A. Scott et al.   AMERICAN JOURNAL OF HUMAN GENETICS

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose

(2008) G. M. Cooper et al.   BLOOD

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin

(2008) BF Gage et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Dosing Algorithms to Predict Warfarin Maintenance Dose in Caucasians and African Americans

(2008) H Schelleman et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

PharmGKB: Understanding the Effects of Individual Genetic Variants

(2008) Katrin Sangkuhl et al.   DRUG METABOLISM REVIEWS

Delivery of Genomic Medicine for Common Chronic Adult Diseases

(2008) Maren T. Scheuner et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Changes in consensus arylamine N-acetyltransferase gene nomenclature

(2008) David W. Hein et al.   Pharmacogenetics and Genomics

Ability of whole-genome SNP arrays to capture ‘must have’ pharmacogenomic variants

(2008) Eric J Peters et al.   PHARMACOGENOMICS

Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use

(2008) Felix W Frueh et al.   PHARMACOTHERAPY